CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Intervention 1 +2 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02550093
NCT02550093Phase 4Completed

The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold: A Randomized, Double Blinded, Crossover Volunteer Study

Northwestern University·interventional·Posted Sep 15, 2015·Updated May 16, 2022

In Brief

A Phase 4 clinical trial evaluating Intervention 1, Washout Period, and 1 other intervention for Healthy. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Oxytocin is neurohypophysial peptide that acts mainly as a neuromodulator in the brain.The vast majority of basic science studies suggested a large effect of oxytocin in minimizing acute pain.Few studies have demonstrated an association between plasma levels of oxytocin and pain in humans. Since addictive properties of oxytocin have not been described, the drug may have important application in the management of acute and chronic pain. No studies have examined the effect of intranasal oxytocin on pain sensitivity and threshold.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 15, 2015
Enrollment StartApr 1, 2015
Primary CompletionAug 1, 2015
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.8 years ago

Interventions

Intervention 1procedure

Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 1 (Day 1).

Washout Periodbehavioral

The wash-out period will be between intervention 1 and intervention 2. 13 days in length.

Intervention 2procedure

Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 2 (Day 14).